Table 2.

Results of Guthrie cards screening in patients with AML

Patient	Molecular marker	Detection sensitivity	% blasts at diagnosis	Age at diagnosis	Guthrie card
AML1	FLT3/ITD	10-5	87%	2 y 9 mo	negative
AML2	FLT3/ITD	10-5	70%	8 y 9 mo	negative
	PML/RARalpha	10-4-10-5			negative
AML3	PML/RARalpha	10-4-10-5	>80%	13 y 9 mo	negative
AML4	PML/RARalpha	10-4	55%	8 y 7 mo	negative
AML5	PML/RARalpha	10-4-10-5	64%	7 y 4 mo	negative
AML6	CBFbeta/MYH11	10-4-10-5	82%	5 y 8 mo	negative
AML7	CBFbeta/MYH11	10-4	70%	6 y 3 mo	negative
AML8	CBFbeta/MYH11	10-3-10-4	30%	2 y 6 mo	negative
AML9	MLL/AF6	10-4-10-5	73%	1 y 5 mo	negative
AML10	MLL/AF9	10-4-10-5	70%	1 y 7 mo	negative
AML11	MLL/AF10	10-4	78%	5 y 4 mo	negative
AML12	AML1/ETO	10-4-10-5	40%	9 y 4 mo	negative
AML13	AML1/ETO	10-3-10-4	5,2%	14 y 8 mo	negative